Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Update on inspection by United States Food & Drug Administration (USFDA)

Regulatory & Legal View source PDF Explain this filing

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.6%Reaction day

₹622.00

prior close

₹644.00

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.3%+4.4% vs market

Pharmaceuticals peers, median of 162sector+0.4%+5.2% vs sector

On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.7

15m

+0.8

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.6+1.3+4.4+0.4+5.2

Next day

+6.8+1.1+5.7+0.8+6.0

+3.5-0.4+3.9-0.5+4.0

+14.1+2.0+12.1+0.5+13.6

+13.3+1.9+11.5+0.2+13.2

+12.1+1.9+10.2+0.4+11.7

+11.7+3.0+8.7+0.9+10.8

15d

+10.9+2.3+8.6+2.8+8.1

+24.3+2.8+21.4+2.6+21.7

+48.6+11.9+36.6+7.4+41.2

+35.4+10.5+24.9+9.7+25.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The USFDA inspected Supriya Lifescience's Lote manufacturing facility in Maharashtra from February 2 to February 6, 2026. The inspection ended with a Form 483 containing just one minor observation. The company says it has already addressed that observation and received the Establishment Inspection Report (EIR) classified as 'Voluntary Action Indicated (VAI)'. VAI is a positive outcome that signals successful closure of the inspection without any mandatory corrective action. The company has reaffirmed its commitment to cGMP compliance across all facilities.

Likely market impact

This is a positive outcome for shareholders — a clean VAI closure removes regulatory overhang and supports continued exports to the US market, which is a key revenue driver for the company.